Kidney Week

Abstract: TH-PO0453

Patients with Newly Diagnosed IgAN Demonstrated Stable eGFR with First-Line Sparsentan (SPAR) over Two Years in the SPARTAN Final Analysis

Session Information

• Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - IgAN
  October 22, 2026 | Location: Exhibit Hall A, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

• 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

• Cheung, Chee Kay, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom

Chee Kay Cheung, MBChB, PhD

• Moody, Stephanie, Travere Therapeutics, Inc., San Diego, California, United States

Stephanie Moody, MS

• Dhaun, Neeraj, University of Edinburgh, Edinburgh, United Kingdom

Neeraj Dhaun, MD, PhD, FASN

• Griffin, Sian V., University Hospital of Wales, Cardiff, United Kingdom

Sian V. Griffin, MD, PhD

• Komers, Radko, Travere Therapeutics, Inc., San Diego, California, United States

Radko Komers, MD, PhD

• Mercer, Alex, JAMCO Pharma Consulting, Stockholm, Sweden

Alex Mercer, PhD

• Sinha, Smeeta, Northern Care Alliance NHS Foundation Trust, Manchester, United Kingdom

Smeeta Sinha, MBChB, PhD

• Szklarzewicz, Justyna, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom

Justyna Szklarzewicz, MS, MSc, RN

• Sayer, Matthew, University of Edinburgh, Edinburgh, United Kingdom

Matthew Sayer, MBBS, MSc

• Willcocks, Lisa, Addenbrooke's Hospital, Cambridge, United Kingdom

Lisa Willcocks, MA, MBBS, PhD

• Barratt, Jonathan, University of Leicester, Department of Cardiovascular Sciences, Leicester, United Kingdom

Jonathan Barratt, MBChB, PhD

Background

SPAR is a non-immunosuppressive dual endothelin and angiotensin receptor antagonist (DEARA) approved in the US and EU for the treatment of adults with IgAN. In the interim analysis of SPARTAN (NCT04663204), first-line treatment with SPAR in RASi-naive incident patients with IgAN resulted in rapid and sustained reductions in proteinuria over 24 weeks. Here, we present the findings from the final 2-year analysis, including change in eGFR.

Methods

Newly diagnosed adult patients with biopsy-proven IgAN, proteinuria ≥0.5 g/d and eGFR ≥30 mL/min/1.73 m² at screening, and no prior treatment with ACEis/ARBs (≤12 months) were enrolled (N=12). SPAR was administered open label for 110 weeks with a 4-week follow-up. Key outcomes in the 2-year analysis included kidney function, proteinuria, and safety.

Results

Mean age at enrollment (SD) was 35.8 (12.2) years, with median (IQR) proteinuria of 1.7 (0.6-3.3) g/d and mean (SD) eGFR of 70.2 (25.0) mL/min/1.73 m². Through 110 weeks, kidney function was well preserved. Least-squares (LS) mean eGFR (95% CI) change from baseline (BL) at 110 weeks was −1.75 (−7.13 to 3.64) (Figure). Chronic (weeks 6 to 110) and total eGFR slopes (95% CI) were −1.11 (−4.34 to 2.12) and −1.54 (−4.63 to 1.55) mL/min/1.73 m²/y, respectively (Figure). LS mean percent change (95% CI) in proteinuria from BL to week 110 was −77% (−86% to −64%), and 75% of patients achieved complete remission of proteinuria (UPE <0.3 g/d) at any time. The most frequent AE was dizziness (58.3% of patients), and 1 patient discontinued treatment due to hypotension after week 6.

Conclusion

In patients newly diagnosed with IgAN, first-line treatment with SPAR resulted in near-physiologic eGFR decline (≈1 mL/min/1.73 m²/y) over 2 years. In addition, a majority of patients reached the KDIGO recommended goal of UPE <0.3 g/d during the study. Taken together, these findings further support the use of SPAR as a treatment approach for IgAN as suggested by the 2025 KDIGO guidelines.

Funding

• Commercial Support – Travere Therapeutics, Inc.